Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041349 | 1.00 | CA2 (0.32) | CA2CA1CYP3A4TSHRNFKB1 | |
| SCHEMBL1073251 | 0.75 | — | — | |
| SCHEMBL2071443 | 0.73 | TP53 (0.35) | — | |
| SCHEMBL396139 | 0.73 | TP53 (0.35) | — | |
| SCHEMBL9127697 | 0.71 | — | — | |
| SCHEMBL31115695 | 0.71 | CA2 (0.39) | CA2CA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6327937 | 0.70 | SMN1; SMN2 (0.38) | TSHRNPSR1 | |
| Potassium Ion SCHEMBL11794893 | 0.69 | — | — | |
| SCHEMBL29715912 | 0.69 | CA2 (0.32) | CA2CA1CYP3A4TSHRNFKB1 | |
| SCHEMBL3557605 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199709-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2024-06-20 | — | — | US | claimed |
| US-11905315-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2024-02-20 | — | — | US | claimed |
| US-20210179672-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | GENISYS CREDIT UNION | 2021-06-17 | — | — | US | claimed |
| EP-2533633-B1 | FUNGICIDAL MIXTURES | LANXESS DISTRIB GMBH (DE) | 2017-02-01 | — | — | EP | claimed |
| WO-2016044655-A2 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC. (US) | 2016-03-24 | — | — | WO | claimed |
| US-20130195997-A1 | FUNGICIDAL MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| EP-2460408-A1 | Nematicidal compositions | deVGen N.V. (BE) | 2012-06-06 | — | — | EP | claimed |
| US-20110319435-A1 | FUNGICIDE MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2011-12-29 | — | — | US | claimed |
| US-20240228396-A9 | METHODS FOR PROMOTING PLANT HEALTH USING FREE ENZYMES AND MICROORGANISMS THAT OVEREXPRESS ENZYMES | SPOGEN BIOTECH INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228395-A9 | METHODS FOR PROMOTING PLANT HEALTH USING FREE ENZYMES AND MICROORGANISMS THAT OVEREXPRESS ENZYMES | SPOGEN BIOTECH INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228394-A9 | METHODS FOR PROMOTING PLANT HEALTH USING FREE ENZYMES AND MICROORGANISMS THAT OVEREXPRESS ENZYMES | SPOGEN BIOTECH INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-12031164-B2 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | SPOGEN BIOTECH INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240199709-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240132419-A1 | METHODS FOR PROMOTING PLANT HEALTH USING FREE ENZYMES AND MICROORGANISMS THAT OVEREXPRESS ENZYMES | SPOGEN BIOTECH INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-6090831-A | FUNGICIDE; BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-07-18 | — | — | US | disclosed |
| US-6054473-A | 1,3-dimethyl-5-fluoro-pyrazole-4-carboxamide derivatives, their preparation and their use as microbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| US-6043377-A | MICROBICIDES USEFUL IN CROP PROTECTION AND IN THE PROTECTION OF MATERIALS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-28 | — | — | US | disclosed |
| US-6013664-A | REACTING THIOPHENE-2-CARBOXYLIC ACID DERIVATIVE WITH AMINE, HYDROXY OR MERCAPTO DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-01-11 | — | — | US | disclosed |
| US-5942528-A | INSECTICIDES, ARACHNICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | disclosed |
| EP-0057027-B1 | FUNGICIDES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12031164-B2 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | ENGASE, LCT, CPB1 | CA2 641/4885CA1 1287/4885CYP3A4 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.